| [ Summary ] |
Online hemodiafiltration (OHDF) as a renal replacement therapy has been developed mainly in Europe. The postdilution method of HDF is commonly used, except in Japan, in which predilution is the major technique.
Accumulating evidence confirms the clinical safety and sustainability of OHDF. Although several randomized controlled trials and published meta-analysis have investigated the advantages of OHDF in the last decade, the superiority of OHDF to conventional HD in terms of morbidity and mortality is still controversial. Recent evidence shows that the clinical benefits associated with OHDF are directly correlated to the total ultrafiltered volume delivered (convective dose). The convective dose needed is still under investigation. |